قالب وردپرس درنا توس
Home / US / Trump Administration Defends Plan to Lower Prescription Drug Prices

Trump Administration Defends Plan to Lower Prescription Drug Prices



WASHINGTON – The Trump administration trumps to reduce prescription drug prices, saying it would be more effective than remedies championed by Democrats.

Democrats have long supported two proposals that Mr. Trump endorsed during the 2016 presidential campaign. The government, they say, should directly negotiate with drug manufacturers to obtain lower prices for Medicare beneficiaries.

In a speech on Monday, the secretary of health and human services dismissed those solutions, which Mr Trump backed away from he promised his plan on Friday, as quack remedies.

"The only way that direct negotiation could possibly save money is by doing something this administration does not believe in: denying access to certain medicines for all." Medicare beneficiaries through rationing, fiat, said the secretary, Alex M. Azar II. "We do not believe either of these proposals would put American patients first.

In the past few years of the year, federal officials have received and received the award more are on the way. Mr. Azar said: "These drugs, including many cancer medications, are typically administered in doctors' offices or outpatient departments under Part.

B of Medicare, which pays the average sales price with a 6 percent markup. Mr. Azar said he was willing to move to the D & D section of Medicare, which deals with private health insurance companies to manage the benefit and negotiate discounts with drugmakers.

There is currently no negotiation at all on drug prices under Part B of Medicare.

Mr. Azar thus suggested that it would be time to re-examine certain consumer protections adopted by the George W. Bush administration in 2005 to ensure that Medicare beneficiaries would have access to "all or much more" in six treatment categories.

"Part D spends about $ 30 billion a year on these drugs, "Mr. Azar said. "That's almost 10 percent of what our entire country spends on drugs each year. Yet part of the plans are in the process of gaining substantial market share. "

Drugmakers have little incentive to negotiate when they know that Medicare's prescription drug plans must cover almost all drugs in the six "protected classes": antidepressants; antipsychotic medicines, schizophrenia and certain related disorders; immunosuppressant drugs, to prevent rejection of organ transplants; anti-epileptic drugs; antiretrovirals used in treating H.I.V./AIDS; and many cancer drugs.

In January 2014, the Obama administration has proposed three back-breaking protections. The administration withdrew the proposal two months later, following a criticism of patients' patience, pharmaceutical companies and members of Congress of both parties.

Mr. Azar said: "The use of prescription drugs.

Drugmakers said Mr. Trump's plans for far-reaching changes in Medicare were misguided. Robert E. Zirkelbach, a spokesman for the Pharmaceutical Research and Manufacturers of America, an industry lobbying group.

Mr. Trump's "blueprint to lower drug prices" included in his 2019 budget request. But Mr. Azar said he did not need to wait for Congress.

As secretary, he said, he can use his pen – "a very powerful pen" – to authorize demonstration projects, and to bring down drug prices.

Mr. Azar's vow recalled the strategy President Barack Obama pursued in his last three years in office. "The ball forward," Mr. Obama said.

Many of Mr Obama's actions have been reversed by the Trump administration.

In another move to reduce prices, Mr. Azar said the trump administration will "call out" brand-name drugmakers

The Generic Drug Administration

The Generic Drug Administration does not require the extensive clinical studies that it provides might otherwise be required. "

" We know that certain brand-name manufacturers are abusing the system by blocking access to samples, "Mr. Azar said, and the FDA

Whether or not such tactics violate the law in any specific case is often a complex question. Mylan, a generic drug company, filing an antitrust suit against Celgene in 2014, asserted that Celgene had maintained monopolies over two of its blockbuster cancer drugs by refusing to share samples. A federal court is still sifting through the factual and legal issues.


Source link